{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:00:06Z","timestamp":1790175606309,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"40","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P50-CA097190"],"award-info":[{"award-number":["P50-CA097190"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA082084"],"award-info":[{"award-number":["T32CA082084"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,10,20]]},"DOI":"10.1038\/s41388-026-03936-0","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:14:57Z","timestamp":1787159697000},"page":"4330-4344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tumor-derived PTX3 drives an immunosuppressive myeloid landscape and inhibits CD8 T cell-mediated anti-tumor immunity via PI3K-dependent signaling"],"prefix":"10.1038","volume":"45","author":[{"given":"Mohamed Y.","family":"Zaky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Vashisht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A. I.","family":"Al-Hatamleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Siddoway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7227-1220","authenticated-orcid":false,"given":"Jennifer","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Bragoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessy","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaibin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangguo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4343-2527","authenticated-orcid":false,"given":"Jing H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"3936_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"3936_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41571-019-0227-z","volume":"16","author":"JD Cramer","year":"2019","unstructured":"Cramer JD, Burtness B, Le QT, Ferris RL. The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019;16:669\u201383.","journal-title":"Nat Rev Clin Oncol"},{"key":"3936_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6:92.","journal-title":"Nat Rev Dis Primers"},{"key":"3936_CR4","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3389\/fimmu.2020.01721","volume":"11","author":"X-W Qiao","year":"2020","unstructured":"Qiao X-W, Jiang J, Pang X, Huang M-C, Tang Y-J, Liang X-H, et al. The evolving landscape of PD-1\/PD-L1 pathway in head and neck cancer. Front Immunol. 2020;11:1721.","journal-title":"Front Immunol"},{"key":"3936_CR5","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856\u201367.","journal-title":"N Engl J Med"},{"key":"3936_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","volume":"81","author":"RL Ferris","year":"2018","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45\u201351.","journal-title":"Oral Oncol"},{"key":"3936_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers16223754","volume":"16","author":"H Jung","year":"2024","unstructured":"Jung H, Kang J, Han KM, Kim H. Prognostic value of pentraxin3 protein expression in human malignancies: a systematic review and meta-analysis. Cancers. 2024;16:1\u201317.","journal-title":"Cancers"},{"key":"3936_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51047-9","volume":"15","author":"S Delliere","year":"2024","unstructured":"Delliere S, Chauvin C, Wong SSW, Gressler M, Possetti V, Parente R, et al. Interplay between host humoral pattern recognition molecules controls undue immune responses against Aspergillus fumigatus. Nat Commun. 2024;15:6966.","journal-title":"Nat Commun"},{"key":"3936_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers16091637","volume":"16","author":"SA Scuderi","year":"2024","unstructured":"Scuderi SA, Ardizzone A, Salako AE, Panto G, De Luca F, Esposito E, et al. Pentraxin 3: a main driver of inflammation and immune system dysfunction in the tumor microenvironment of glioblastoma. Cancers. 2024;16:1\u201319.","journal-title":"Cancers"},{"key":"3936_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms232315302","volume":"23","author":"M Bogdan","year":"2022","unstructured":"Bogdan M, Meca AD, Turcu-Stiolica A, Oancea CN, Kostici R, Surlin MV, et al. Insights into the relationship between pentraxin-3 and cancer. Int J Mol Sci. 2022;23:1\u201322.","journal-title":"Int J Mol Sci"},{"key":"3936_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.724","volume":"12","author":"YW Hsiao","year":"2022","unstructured":"Hsiao YW, Chi JY, Li CF, Chen LY, Chen YT, Liang HY, et al. Disruption of the pentraxin 3\/CD44 interaction as an efficient therapy for triple-negative breast cancers. Clin Transl Med. 2022;12:e724.","journal-title":"Clin Transl Med"},{"key":"3936_CR12","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/mc.23162","volume":"59","author":"SMY Chen","year":"2020","unstructured":"Chen SMY, Krinsky AL, Woolaver RA, Wang X, Chen Z, Wang JH. Tumor immune microenvironment in head and neck cancers. Mol Carcinog. 2020;59:766\u2013774.","journal-title":"Mol Carcinog"},{"key":"3936_CR13","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cell.2018.05.060","volume":"174","author":"E Azizi","year":"2018","unstructured":"Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. 2018;174:1293\u2013308.e1236.","journal-title":"Cell"},{"key":"3936_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41591-018-0096-5","volume":"24","author":"D Lambrechts","year":"2018","unstructured":"Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, et al. Phenotype molding of stromal cells in the lung tumor microenvironment. Nat Med. 2018;24:1277\u201389.","journal-title":"Nat Med"},{"key":"3936_CR15","first-page":"2558","volume":"40","author":"L Gao","year":"2018","unstructured":"Gao L, Zhang W, Zhong WQ, Liu ZJ, Li HM, Yu ZL, et al. Tumor associated macrophages induce epithelial to mesenchymal transition via the EGFR\/ERK1\/2 pathway in head and neck squamous cell carcinoma. Oncol Rep. 2018;40:2558\u201372.","journal-title":"Oncol Rep"},{"key":"3936_CR16","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1073\/pnas.0915000107","volume":"107","author":"EE Ghosn","year":"2010","unstructured":"Ghosn EE, Cassado AA, Govoni GR, Fukuhara T, Yang Y, Monack DM, et al. Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc Natl Acad Sci USA. 2010;107:2568\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3936_CR17","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3389\/fonc.2019.00656","volume":"9","author":"AT Kumar","year":"2019","unstructured":"Kumar AT, Knops A, Swendseid B, Martinez-Outschoom U, Harshyne L, Philp N, et al. Prognostic significance of tumor-associated macrophage content in head and neck squamous cell carcinoma: a meta-analysis. Front Oncol. 2019;9:656.","journal-title":"Front Oncol"},{"key":"3936_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/816460","volume":"2015","author":"T Roszer","year":"2015","unstructured":"Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015;2015:816460.","journal-title":"Mediators Inflamm"},{"key":"3936_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","volume":"10","author":"L Yang","year":"2017","unstructured":"Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10:58.","journal-title":"J Hematol Oncol"},{"key":"3936_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fcell.2018.00038","volume":"6","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Kitamura T. Targeting tumor-associated macrophages as a potential strategy to enhance the response to immune checkpoint inhibitors. Front Cell Dev Biol. 2018;6:38.","journal-title":"Front Cell Dev Biol"},{"key":"3936_CR21","volume":"2010","author":"A Duray","year":"2010","unstructured":"Duray A, Demoulin S, Hubert P, Delvenne P, Saussez S. Immune suppression in head and neck cancers: a review. Clin Dev Immunol. 2010;2010:701657.","journal-title":"Clin Dev Immunol"},{"key":"3936_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.addr.2017.04.010","volume":"114","author":"C Ngambenjawong","year":"2017","unstructured":"Ngambenjawong C, Gustafson HH, Pun SH. Progress in tumor-associated macrophage (TAM)-targeted therapeutics. Adv Drug Deliv Rev. 2017;114:206\u201321.","journal-title":"Adv Drug Deliv Rev"},{"key":"3936_CR23","doi-asserted-by":"publisher","first-page":"1596004","DOI":"10.1080\/2162402X.2019.1596004","volume":"8","author":"I Larionova","year":"2019","unstructured":"Larionova I, Cherdyntseva N, Liu T, Patysheva M, Rakina M, Kzhyshkowska J. Interaction of tumor-associated macrophages and cancer chemotherapy. Oncoimmunology. 2019;8:1596004.","journal-title":"Oncoimmunology"},{"key":"3936_CR24","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-22-3313","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong DS, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EEW, et al. Eganelisib, a first-in-class PI3Kgamma inhibitor, in patients with advanced solid tumors: results of the phase 1\/1b MARIO-1 trial. Clin Cancer Res. 2023;29:2210\u20139.","journal-title":"Clin Cancer Res"},{"key":"3936_CR25","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1002\/eji.201343349","volume":"43","author":"E Schouppe","year":"2013","unstructured":"Schouppe E, Mommer C, Movahedi K, Laoui D, Morias Y, Gysemans C, et al. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events. Eur J Immunol. 2013;43:2930\u201342.","journal-title":"Eur J Immunol"},{"key":"3936_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12307-012-0126-7","volume":"6","author":"V Umansky","year":"2013","unstructured":"Umansky V, Sevko A. Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron. 2013;6:169\u201377.","journal-title":"Cancer Microenviron"},{"key":"3936_CR27","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","volume":"9","author":"R Weber","year":"2018","unstructured":"Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol. 2018;9:1310.","journal-title":"Front Immunol"},{"key":"3936_CR28","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3389\/fimmu.2018.00398","volume":"9","author":"V Fleming","year":"2018","unstructured":"Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front Immunol. 2018;9:398.","journal-title":"Front Immunol"},{"key":"3936_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/srep24506","volume":"6","author":"W He","year":"2016","unstructured":"He W, Liang P, Guo G, Huang Z, Niu Y, Dong L, et al. Re-polarizing myeloid-derived suppressor cells (MDSCs) with cationic polymers for cancer immunotherapy. Sci Rep. 2016;6:24506.","journal-title":"Sci Rep"},{"key":"3936_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.126853","volume":"4","author":"L Sun","year":"2019","unstructured":"Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S. et al. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight. 2019;4:1\u201312.","journal-title":"JCI Insight"},{"key":"3936_CR31","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.cell.2018.09.030","volume":"175","author":"MM Gubin","year":"2018","unstructured":"Gubin MM, Esaulova E, Ward JP, Malkova ON, Runci D, Wong P, et al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell. 2018;175:1014\u201330.e1019.","journal-title":"Cell"},{"key":"3936_CR32","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.3892\/or.2017.5575","volume":"37","author":"S Sumi","year":"2017","unstructured":"Sumi S, Umemura N, Takayama E, Ohkoshi E, Adachi M, Mizuno-Kamiya M, et al. Metastasized murine oral squamous cell carcinoma cells induce intratumoral polymorphonuclear myeloid derived suppressor cells. Oncol Rep. 2017;37:2897\u2013904.","journal-title":"Oncol Rep"},{"key":"3936_CR33","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.4049\/jimmunol.1501293","volume":"196","author":"RH Younis","year":"2016","unstructured":"Younis RH, Han KL, Webb TJ. Human head and neck squamous cell carcinoma-associated semaphorin 4D induces expansion of myeloid-derived suppressor cells. J Immunol. 2016;196:1419\u201329.","journal-title":"J Immunol"},{"key":"3936_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.","journal-title":"Nat Commun"},{"key":"3936_CR35","doi-asserted-by":"publisher","first-page":"e0119662","DOI":"10.1371\/journal.pone.0119662","volume":"10","author":"B Hochst","year":"2015","unstructured":"Hochst B, Mikulec J, Baccega T, Metzger C, Welz M, Peusquens J, et al. Differential induction of Ly6G and Ly6C positive myeloid derived suppressor cells in chronic kidney and liver inflammation and fibrosis. PLoS ONE. 2015;10:e0119662.","journal-title":"PLoS ONE"},{"key":"3936_CR36","doi-asserted-by":"publisher","first-page":"977","DOI":"10.4049\/jimmunol.179.2.977","volume":"179","author":"P Sinha","year":"2007","unstructured":"Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007;179:977\u201383.","journal-title":"J Immunol"},{"key":"3936_CR37","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","volume":"517","author":"N Cancer Genome Atlas","year":"2015","unstructured":"Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576\u201382.","journal-title":"Nature"},{"key":"3936_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41556-018-0260-7","volume":"21","author":"PH Liu","year":"2019","unstructured":"Liu PH, Shah RB, Li Y, Arora A, Ung PM, Raman R, et al. An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. Nat Cell Biol. 2019;21:203\u201313.","journal-title":"Nat Cell Biol"},{"key":"3936_CR39","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00439-014-1470-0","volume":"134","author":"DL Masica","year":"2015","unstructured":"Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, et al. Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Hum Genet. 2015;134:497\u2013507.","journal-title":"Hum Genet"},{"key":"3936_CR40","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1056\/NEJMoa073770","volume":"357","author":"ML Poeta","year":"2007","unstructured":"Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552\u201361.","journal-title":"N Engl J Med"},{"key":"3936_CR41","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1158\/0008-5472.CAN-14-2735","volume":"75","author":"DM Neskey","year":"2015","unstructured":"Neskey DM, Osman AA, Ow TJ, Katsonis P, McDonald T, Hicks SC, et al. Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer. Cancer Res. 2015;75:1527\u201336.","journal-title":"Cancer Res"},{"key":"3936_CR42","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1158\/0008-5472.CAN-14-2729","volume":"75","author":"AA Osman","year":"2015","unstructured":"Osman AA, Neskey DM, Katsonis P, Patel AA, Ward AM, Hsu TK, et al. Evolutionary action score of TP53 coding variants is predictive of platinum response in head and neck cancer patients. Cancer Res. 2015;75:1205\u201315.","journal-title":"Cancer Res"},{"key":"3936_CR43","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1158\/1078-0432.CCR-11-2260","volume":"18","author":"HD Skinner","year":"2012","unstructured":"Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res. 2012;18:290\u2013300.","journal-title":"Clin Cancer Res"},{"key":"3936_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21186585","volume":"21","author":"SMY Chen","year":"2020","unstructured":"Chen SMY, Li B, Nicklawsky AG, Krinsky AL, Brunetti T, Woolaver RA, et al. Deletion of p53 and hyper-activation of PIK3CA in Keratin-15(+) stem cells lead to the development of spontaneous squamous cell carcinoma. Int J Mol Sci. 2020;21:1\u201316.","journal-title":"Int J Mol Sci"},{"key":"3936_CR45","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13046-022-02337-x","volume":"41","author":"SMY Chen","year":"2022","unstructured":"Chen SMY, Popolizio V, Woolaver RA, Ge H, Krinsky AL, John J, et al. Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers. J Exp Clin Cancer Res. 2022;41:123.","journal-title":"J Exp Clin Cancer Res"},{"key":"3936_CR46","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/0008-5472.CAN-11-1831","volume":"72","author":"NP Judd","year":"2012","unstructured":"Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS Jr, et al. ERK1\/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 2012;72:365\u201374.","journal-title":"Cancer Res"},{"key":"3936_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms252212277","volume":"25","author":"MY Zaky","year":"2024","unstructured":"Zaky MY, John J, Vashisht M, Singh P, Al-Hatamleh MAI, Siddoway K, et al. Targeting myeloid cells in head and neck squamous cell carcinoma: a kinase inhibitor library screening approach. Int J Mol Sci. 2024;25:1\u201313.","journal-title":"Int J Mol Sci"},{"key":"3936_CR48","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556\u2013W560.","journal-title":"Nucleic Acids Res"},{"key":"3936_CR49","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.18632\/oncotarget.23751","volume":"9","author":"P Zolkind","year":"2018","unstructured":"Zolkind P, Przybylski D, Marjanovic N, Nguyen L, Lin T, Johanns T, et al. Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma. Oncotarget. 2018;9:4109\u201319.","journal-title":"Oncotarget"},{"key":"3936_CR50","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14:5198\u2013208.","journal-title":"Clin Cancer Res"},{"key":"3936_CR51","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jneuroim.2013.04.009","volume":"260","author":"M Locatelli","year":"2013","unstructured":"Locatelli M, Ferrero S, Martinelli Boneschi F, Boiocchi L, Zavanone M, Maria Gaini S, et al. The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. J Neuroimmunol. 2013;260:99\u2013106.","journal-title":"J Neuroimmunol"},{"key":"3936_CR52","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1158\/0008-5472.CAN-09-2335","volume":"70","author":"G Germano","year":"2010","unstructured":"Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010;70:2235\u201344.","journal-title":"Cancer Res"},{"key":"3936_CR53","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1158\/1078-0432.CCR-10-3024","volume":"17","author":"EP Diamandis","year":"2011","unstructured":"Diamandis EP, Goodglick L, Planque C, Thornquist MD. Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res. 2011;17:2395\u20139.","journal-title":"Clin Cancer Res"},{"key":"3936_CR54","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/jvh.12472","volume":"23","author":"RF Carmo","year":"2016","unstructured":"Carmo RF, Aroucha D, Vasconcelos LR, Pereira LM, Moura P, Cavalcanti MS. Genetic variation in PTX3 and plasma levels associated with hepatocellular carcinoma in patients with HCV. J Viral Hepat. 2016;23:116\u201322.","journal-title":"J Viral Hepat"},{"key":"3936_CR55","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1158\/0008-5472.CAN-14-0369","volume":"74","author":"G Stallone","year":"2014","unstructured":"Stallone G, Cormio L, Netti GS, Infante B, Selvaggio O, Fino GD, et al. Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer. Cancer Res. 2014;74:4230\u20138.","journal-title":"Cancer Res"},{"key":"3936_CR56","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/ijc.29822","volume":"138","author":"M Infante","year":"2016","unstructured":"Infante M, Allavena P, Garlanda C, Nebuloni M, Morenghi E, Rahal D, et al. Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients. Int J Cancer. 2016;138:983\u201391.","journal-title":"Int J Cancer"},{"key":"3936_CR57","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1158\/1535-7163.MCT-11-0286","volume":"10","author":"D Leali","year":"2011","unstructured":"Leali D, Alessi P, Coltrini D, Ronca R, Corsini M, Nardo G, et al. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors. Mol Cancer Ther. 2011;10:1600\u201310.","journal-title":"Mol Cancer Ther"},{"key":"3936_CR58","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1182\/blood-2003-10-3433","volume":"104","author":"M Rusnati","year":"2004","unstructured":"Rusnati M, Camozzi M, Moroni E, Bottazzi B, Peri G, Indraccolo S, et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood. 2004;104:92\u20139.","journal-title":"Blood"},{"key":"3936_CR59","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccell.2015.07.002","volume":"28","author":"R Ronca","year":"2015","unstructured":"Ronca R, Giacomini A, Di Salle E, Coltrini D, Pagano K, Ragona L, et al. Long-pentraxin 3 derivative as a small-molecule FGF trap for cancer therapy. Cancer Cell. 2015;28:225\u201339.","journal-title":"Cancer Cell"},{"key":"3936_CR60","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/nature07468","volume":"456","author":"J Lu","year":"2008","unstructured":"Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. Structural recognition and functional activation of FcgammaR by innate pentraxins. Nature. 2008;456:989\u201392.","journal-title":"Nature"},{"key":"3936_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2023.117592","volume":"551","author":"Y Li","year":"2023","unstructured":"Li Y, Zhang S, Liu J, Zhang Y, Zhang N, Cheng Q, et al. The pentraxin family in autoimmune disease. Clin Chim Acta. 2023;551:117592.","journal-title":"Clin Chim Acta"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03936-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03936-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03936-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:04:51Z","timestamp":1790172291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03936-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":61,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2026,10,20]]}},"alternative-id":["3936"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03936-0","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Animal work was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Pittsburgh (Pittsburgh, PA) (IACUC Protocol #: 24024533). No human subjects were included in the study.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}